The ethics of using safe gene therapies to improve the health and cognition of Down syndrome children and adults.

A medical team treated the infant KJ for a rare genetic disorder using gene-editing therapy from February to April 2025, achieving a breakthrough that could help millions, according to two statements.

Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

The cost of sequencing DNA has dropped dramatically, and with technologies like CRISPR, gene editing is becoming more precise and powerful than ever. From curing genetic diseases to designing the next ...

DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...

A team of doctors and scientists has used a tailor-made gene-editing therapy to treat an infant with a rare genetic condition, a medical first that opens the door to a new era of individualized ...

That is because scientists keen to achieve more precise control over an organism’s genetics are experimenting with a ...

CRISPR functions as a programmable genetic memory system derived from bacterial immune defenses against viral infections. Guide RNA allows for rapid multiplexed targeting compared to older ...

In May 2025, the world celebrated the success of KJ, an infant who was treated with the world’s first personalized CRISPR gene editing therapy. KJ was born with severe carbamoyl phosphate synthetase 1 ...

Please provide your email address to receive an email when new articles are posted on . In this video, Mark Sulkowski, MD, discusses clinical trials in gene editing therapy and basic studies in ...

From curing rare diseases to sparking debates about designer babies, genetic engineering is moving from sci-fi into everyday life. CRISPR and other tools are now delivering real therapies while ...

Forbes contributors publish independent expert analyses and insights. A patient in a late-stage gene editing trial for a rare heart condition died from fatal liver complications after receiving an ...